Pancreatic Ductal Adenocarcinoma Pipeline: Shaping the Future with 80+ Innovators Advancing Breakthrough Therapies

The pancreatic ductal adenocarcinoma market is rapidly advancing and fueled by groundbreaking research and innovative therapies from companies such as Eucure Biopharma, Panbela Therapeutics, and Jeil Pharmaceutical. These industry pioneers are transforming treatment strategies and redefining the future of Pancreatic Ductal Adenocarcinoma care, bringing new hope to patients worldwide.

DelveInsight's "Pancreatic Ductal Adenocarcinoma Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Pancreatic Ductal Adenocarcinoma market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging Pancreatic Ductal Adenocarcinoma drugs, the Pancreatic Ductal Adenocarcinoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report
• DelveInsight's Pancreatic Ductal Adenocarcinoma Pipeline analysis depicts a robust space with 80+ active players working to develop 80+ pipeline drugs for Pancreatic Ductal Adenocarcinoma treatment.
• The leading Pancreatic Ductal Adenocarcinoma companies include Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others are evaluating their lead assets to improve the Pancreatic Ductal Adenocarcinoma treatment landscape.
• Key Pancreatic Ductal Adenocarcinoma pipeline therapies in various stages of development include Onvansertib, Nadunolimab, Zimberelimab, Mitazalimab, Elraglusib, and others.
• In February 2025, Alligator Bioscience announced the successful completion of its End of Phase 2 (EOP2) interaction with the FDA, paving the way for a Phase 3 trial in 2025. The trial will test mitazalimab as a first-line treatment for metastatic pancreatic cancer in combination with mFOLFIRINOX.
• In February 2025, Alpha Tau Medical Ltd. announced FDA approval of an Investigational Device Exemption (IDE) supplement for its Alpha DaRT® cancer therapy. This approval expands a clinical study, initially approved in January 2025, to include a broader group of pancreatic cancer patients, exploring the combination of Alpha DaRT and first-line chemotherapy.
• In January 2025, the FDA granted Fast Track Designation to LOAd703, an oncolytic adenovirus with transgenes encoding 4-1BBL and TMZ-CD40L, for the potential treatment of pancreatic cancer. LOAd703 is currently being evaluated in the Phase 1/2 LOKON001 trial, assessing its safety and feasibility in combination with chemotherapy for patients with unresectable or metastatic advanced PDAC.
• In January 2025, Elicio Therapeutics, Inc.announced it received supportive feedback from the U.S. FDA in an End of Phase 1 Type B meeting regarding the registrational strategy for ELI-002. Based on the feedback, Elicio plans to file a Biologics License Application (BLA), contingent on results from a planned Phase 3 trial.

Request a sample and discover the recent breakthroughs happening in the Pancreatic Ductal Adenocarcinoma pipeline landscape @ https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pancreatic Ductal Adenocarcinoma Overview
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, with a 5-year survival rate of less than 10%. Most patients are diagnosed at an advanced, unresectable, or metastatic stage, as the disease often progresses silently, with symptoms emerging only in later stages. The complexity of PDAC's genetic and cellular landscape contributes to its poor prognosis, with extensive mutational changes driving tumor growth and resistance to treatment. Additionally, the lack of effective early detection methods further complicates timely diagnosis, making PDAC particularly challenging to treat.

Find out more about Pancreatic Ductal Adenocarcinoma medication @ https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pancreatic Ductal Adenocarcinoma Treatment Analysis: Drug Profile
Onvansertib: Cardiff Oncology
Onvansertib is an oral, highly selective PLK1 inhibitor being developed for use in combination with standard-of-care (SOC) therapies. It is currently being evaluated in clinical programs for KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma (PDAC), and metastatic castrate-resistant prostate cancer. The development strategy aims to exploit tumor vulnerabilities, overcome treatment resistance, and enhance clinical outcomes compared to existing SOC treatments.

Nadunolimab: Cantargia
Nadunolimab is a humanized, fucose-lacking monoclonal antibody developed by Cantargia for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) and pancreatic cancer. It is a first-in-class anti-IL1RAP antibody, currently being evaluated in five Phase I/II trials, primarily for PDAC and NSCLC, in combination with chemotherapy or checkpoint inhibitors. Nadunolimab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits IL-1α and IL-1β signaling, helping counteract immune suppression and chemotherapy resistance in the tumor microenvironment.

Key Pancreatic Ductal Adenocarcinoma Therapies and Companies
• Onvansertib: Cardiff Oncology
• Nadunolimab: Cantargia
• Zimberelimab: Arcus Biosciences
• Mitazalimab (ADC-1013): Alligator Bioscience
• Elraglusib (9 ING 41): Actuate Therapeutics

Learn more about the novel and emerging Pancreatic Ductal Adenocarcinoma pipeline therapies @ https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Pancreatic Ductal Adenocarcinoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous

By Molecule Type
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Pancreatic Ductal Adenocarcinoma Pipeline Report
• Coverage: Global
• Key Pancreatic Ductal Adenocarcinoma Companies: Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others.
• Key Pancreatic Ductal Adenocarcinoma Pipeline Therapies: Onvansertib, Nadunolimab, Zimberelimab, Mitazalimab, Elraglusib, and others.

Dive deep into rich insights for drugs used for Pancreatic Ductal Adenocarcinoma treatment; visit @ https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Pancreatic Ductal Adenocarcinoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics
6. Pancreatic Ductal Adenocarcinoma Pipeline: Late-Stage Products (Phase III)
7. Pancreatic Ductal Adenocarcinoma Pipeline: Late-Stage Products (Phase III)
8. Pancreatic Ductal Adenocarcinoma Pipeline: Mid-Stage Products (Phase II)
9. Pancreatic Ductal Adenocarcinoma Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.